| Autor: |
Rehman ST; Medicine, Aga Khan University Medical College Pakistan, Karachi, Pakistan., Azeem SM; Ziauddin Medical University, Ziauddin University, Karachi, Pakistan., Akbar A; Liaquat College of Medicine and Dentistry, Karachi, Pakistan., Shafiq O; The Aga Khan University, Karachi, Pakistan., Azeem SS; Ziauddin Medical University, Ziauddin University, Karachi, Pakistan., Ali SHA; Department of Oncology, Ziauddin Medical University, Ziauddin University, Karachi, Pakistan. |
| Jazyk: |
angličtina |
| Zdroj: |
Journal of chemotherapy (Florence, Italy) [J Chemother] 2024 Jul; Vol. 36 (4), pp. 329-333. Date of Electronic Publication: 2023 Oct 14. |
| DOI: |
10.1080/1120009X.2023.2267896 |
| Abstrakt: |
Nivolumab is an anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody and was the first immune checkpoint inhibitor drug approved for use in advanced non-small cell lung cancer (NSCLC). In this report, we describe a rare case of Lambert-Eaton myasthenic syndrome (LEMS), which developed as a side effect of nivolumab in a patient with metastatic lung squamous cell carcinoma. Our patient, who was previously treated with nivolumab for metastatic squamous cell carcinoma of the lung, appeared with a headache, swollen face, dysarthria, asthenia, xerostomia, and drooping eyelid. Early testing indicated no thymomas or newly developing tumors in whole-body scans, and the blood workup was normal. We came to the conclusion that nivolumab-induced LEMS was the cause of the symptoms after performing nerve conduction investigations ruling out other differentials. We believe our clinical experience of this rare and unexpected adverse event should be shared. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
